Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1394results about How to "Toxic reduction" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods and compositions useful for administration of chemotherapeutic agents
InactiveUS6096331AReduce morbidityLow toxicityPowder deliveryEchographic/ultrasound-imaging preparationsActive agentIn vivo
In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of a pharmaceutically active agent, wherein the agent is associated with a polymeric biocompatible material.
Owner:ABRAXIS BIOSCI LLC
Treatment of biomass to obtain fermentable sugars
InactiveUS20070031918A1Toxic reductionReduce needBiological substance pretreatmentsByproduct vaporizationFermentable sugarCompound (substance)
Biomass is pretreated using a low concentration of aqueous ammonia at high biomass concentration. Pretreated biomass is further hydrolyzed with a saccharification enzyme consortium. Fermentable sugars released by saccharification may be utilized for the production of target chemicals by fermentation.
Owner:ALLIANCE FOR SUSTAINABLE ENERGY +1
Desalination methods and systems that include carbonate compound precipitation
ActiveUS20090001020A1Easy complianceImprove desalination efficiencyGeneral water supply conservationSeawater treatmentSaline waterDesalination
Desalination methods that include carbonate compound precipitation are provided. In certain embodiments, feed water is subjected to carbonate compound precipitation conditions prior to desalination. In certain embodiments, desalination waste brine is subjected to carbonate compound precipitation conditions. In yet other embodiments, both feed water and waste brine are subjected to carbonate compound precipitation conditions. Aspects of embodiments of the invention include carbone dioxide sequestration. Embodiments of the invention further employ a precipitate product of the carbonate compound precipitation conditions as a building material, e.g., a cement. Also provided are systems configured for use in methods of the invention.
Owner:ARELAC INC
Compositions and methods for treatment of viral diseases
InactiveUS20080161324A1Slow and stop replicationReduce loadBiocideMicrobiological testing/measurementSingle-Stranded RNADisease
The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.
Owner:EXCRX SINGAPORE PTE +1
Treatment of biomass to obtain ethanol
ActiveUS20070031953A1Toxic reductionReduce needBiological substance pretreatmentsByproduct vaporizationChemistryBiomass
Owner:ALLIANCE FOR SUSTAINABLE ENERGY +1
Immunostimulatory nucleic acid molecules for activating dendritic cells
InactiveUS20070065467A1Th responseEffective adjuvantOrganic active ingredientsSugar derivativesDendritic cellPyrimidine Nucleotides
Owner:UNIV OF IOWA RES FOUND
IL-2 selective agonists and antagonists
InactiveUS6955807B1Great therapeutic useToxic reductionBacteriaSugar derivativesNatural Killer Cell Inhibitory ReceptorsNucleotide
The invention is directed to a polypeptide comprising a human IL-2 mutein numbered in accordance with wild-type IL-2 wherein said human IL-2 is substituted at at least one of positions 20, 88 or 126, whereby said mutein preferentially activates T cells over NK cells. D20H and I, N88G, I, and R, in particular have a relative T cell-differential activity much greater than native IL-2, with predicted associated reduced in vivo toxicity. The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
Owner:AICURIS GMBH & CO KG
Methods and reagents for the treatment of metabolic disorders
InactiveUS20060069161A1Reduced glucose levelHigh expressionOrganic active ingredientsSenses disorderDiabetes mellitusObesity
The invention features compositions, methods, and kits for the treatment of metabolic disorders such as diabetes and obesity.
Owner:ZALICUS INC
Compositions and methods for treatment of viral diseases
InactiveUS20100009970A1Slow and stop replicationReduce loadBiocideNervous disorderSingle-Stranded RNADisease
The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.
Owner:EXCRX SINGAPORE PTE +1
Combination therapy for the treatment of immunoinflammatory disorders
InactiveUS20070110685A1Great efficacyMore treatment satisfactionBiocideCosmetic preparationsVitamin D CompoundCompound (substance)
The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a non-steroidal immunophilin-dependent immunosuppressant (NsIDI) and a Group A enhancer (e.g., antifungal agent, antigout agent, anti-infective agent, antiprotozoal agent, antiviral agent, humectant, sunscreen, vitamin D compound, microtubuline inhibitor, or zinc salt) or analog or metabolite thereof to the patient. The invention also features a pharmaceutical composition containing an NsIDI and Group A enhancer or analog or metabolite thereof for the treatment or prevention of an immunoinflammatory disorder.
Owner:ZALICUS INC
Bivalent SMAC mimetics and the uses thereof
ActiveUS20080089896A1Toxic reductionMore tolerableBiocideOrganic chemistrySmac mimeticsSensitized cell
The invention relates to bivalent mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.
Owner:RGT UNIV OF MICHIGAN
Conjugates comprising a biodegradable polymer and uses therefor
InactiveUS20050169968A1Improve biological activityProlong half-life in vivoPeptide/protein ingredientsPharmaceutical non-active ingredientsActive agentThrombosis prevention
Biologically active agents covalently linked to a polymer. The polymer is preferably a biodegradable polymer are provided. The biologically active agent is preferably a protein, such as an extracellular soluble protein, e.g., an extracellular enzyme. The enzyme can be an apyrase, e.g., NTPDase. Conjugates of the invention can be used as therapeutics in subjects. For example, a conjugate comprising an apyrase can be used for treating and preventing thrombosis, atherosclerotic plaque complications and vascular disorders.
Owner:MERSANA THERAPEUTICS INC +1
Small molecule inhibitors of MDM2 and the uses thereof
InactiveUS7759383B2Extended half-lifeIncrease the function(s) of p53BiocideOrganic chemistrySensitized cellMdm2 Protein
Owner:RGT UNIV OF MICHIGAN
Teeth whitening compositions and methods
InactiveUS20100266989A1Less toxicEffective sensitivityCosmetic preparationsBiocideEosin BErythrosine B
Disclosed herein are teeth whitening compositions generally including an oxidizing agent (e.g., a peroxide), and an activating agent that has an emission wavelength between about 400 nm and about 570 nm (e.g., Eosin B, Eosin Y, or Erythrosine B). Methods of employing these compositions to whiten teeth, methods of making these compositions and kits that include some or part of the composition ingredients, are also described.
Owner:KLOX TECH
Self healing composite material and method of manufacturing same
InactiveUS20090036568A1Large operating rangeFaster rate of healingRadio transmissionThin material handlingEmulsionRestorative material
A self-healing material comprises a matrix embedded with micro-pockets of a healing-agent releasable by a crack in the matrix. The healing-agent is able to bond to the matrix to repair the crack. The healing-agent is contained in microcapsules. A corresponding catalyst for the healing-agent is embedded in the matrix and contained in a plurality of microcapsules as an emulsion. The emulsion comprises an oil, a perfluorated solvent, a hydrophobic ionic liquid, or mixtures thereof. A method of manufacturing the self-healing material comprises the steps of identifying an operational temperature range of the material, providing at least one substance as the healing-agent, which substance remaining substantially in a liquid state within the operational temperature range, identifying an operational evaporation rate of the healing-agent and providing the substance with a curing time according to the evaporation rate.
Owner:MPB COMM +1
Novel compounds with high therapeutic index
ActiveUS20060241017A1Improve bioavailability and efficacyLess toxicBiocideAntipyreticAmino acid compositionCompound (substance)
The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced pharmacological and pharmaceutical properties. In fact, the novel drug derivatives of the present invention enhance at least one therapeutic quality, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.
Owner:SIGNATURE R & D HLDG LLC
Desalination methods and systems that include carbonate compound precipitation
InactiveUS20100154679A1Easy complianceImprove desalination efficiencyAuxillariesGeneral water supply conservationSaline waterDesalination
Desalination methods that include carbonate compound precipitation are provided. In certain embodiments, feed water is subjected to carbonate compound precipitation conditions prior to desalination. In certain embodiments, desalination waste brine is subjected to carbonate compound precipitation conditions. In yet other embodiments, both feed water and waste brine are subjected to carbonate compound precipitation conditions. Aspects of embodiments of the invention include carbon dioxide sequestration. Embodiments of the invention further employ a precipitate product of the carbonate compound precipitation conditions as a building material, e.g., a cement. Also provided are systems configured for use in methods of the invention.
Owner:CALERA CORP
Controlling plant pathogens with bacterial/fungal antagonist combinations
Fungal / bacterial antagonist combinations, a seed coated with one of the combinations and a plant protected from plant pathogens by one of the combinations. The invention is also a fungal / bacterial antagonist combination comprising a Trichoderma virens fungal antagonist and a Bacillus subtilis var. amyloliquefaciens (Bacillus amyloliquefaciens) bacterial antagonist and its use for controlling plant pathogens as a biocontrol agent, bio-pesticide or bio-fungicide. The invention also finds utility as a fungal / bacterial antagonist combination applied to the seed, stalk or leaf that results in an increase in plant yield. Control of early and late season stalk and root rot caused by fungi such as Fusarium, Phythium, Phytophthora and Penicillium in tomatoes, peppers, turf grass, soybeans, sunflower, wheat and corn is achieved.
Owner:NOVOZYMES BIOAG AS
Indole inhibitors of MDM2 and the uses thereof
InactiveUS7737174B2Growth inhibitionExtended half-lifeBiocideOrganic chemistrySensitized cellMdm2 Protein
Owner:RGT UNIV OF MICHIGAN
Methods and reagents for the treatment of immunoinflammatory disorders
InactiveUS20050192261A1Great efficacyMore treatment satisfactionBiocideNervous disorderDrugAntihistamine
The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient an antihistamine, either alone or in combination with one or more additional agents. The invention also features a pharmaceutical composition containing an antihistamine in combination with one or more additional agents.
Owner:COMBINATORX
Method and structure for adhesion of absorber material for thin film photovoltaic cell
InactiveUS20100081230A1Toxic reductionImprove bindingSemiconductor/solid-state device manufacturingPhotovoltaic energy generationIndiumSulfur
A method for forming a thin film photovoltaic device includes providing a transparent substrate comprising a surface region and forming a first electrode layer overlying the surface region. The method further includes forming a thin layer of copper gallium material overlying the first electrode layer to act as an intermediary adhesive layer to facilitate attachment to the first electrode layer. Additionally, the method includes forming a copper layer overlying the thin layer and forming an indium layer overlying the copper layer to form a multilayered structure and subjecting the multilayered structure to thermal treatment process with sulfur bearing species to form a copper indium disulfide alloy material. The copper indium disulfide alloy material comprises a copper:indium atomic ratio of about 1.2:1 to about 3.0:1 overlying a copper gallium disulfide material converted from the thin layer. Furthermore, the method includes forming a window layer overlying the copper indium disulfide alloy material.
Owner:CM MFG
Polymeric antioxidants
InactiveUS7223432B2Toxic reductionImprove thermal stabilityFatty substance preservation using additivesFood preservationArylPolymer science
Antioxidant polymers of the present invention comprise repeat units that include one or both of Structural Formulas (I) and (II):wherein:R is —H or a substituted or unsubstituted alkyl, acyl or aryl group;Ring A is substituted with at least one tert-butyl group or substituted or unsubstituted n-alkoxycarbonyl group;Ring B is substituted with at least one —H and at least one tert-butyl group or substituted or unsubstituted n-alkoxycarbonyl group;Rings A and B are each optionally substituted with one or more groups selected from the group consisting of —OH, —NH, —SH, a substituted or unsubstituted alkyl or aryl group, and a substituted or unsubstituted alkoxycarbonyl group;n is an integer equal to or greater than 2; andp is an integer equal to or greater than 0.The invention also includes methods of using and preparing these polymers.
Owner:UNIVERSITY OF MASSACHUSETTS LOWELL +1
Desalination methods and systems that include carbonate compound precipitation
ActiveUS20100158786A1Easy complianceImprove desalination efficiencyCalcium/strontium/barium carbonatesAuxillariesSaline waterDesalination
Owner:ARELAC INC
Conformationally Constrained Smac Mimetics and the Uses Thereof
ActiveUS20080269140A1High expressionToxic reductionDipeptide ingredientsTripeptide ingredientsSmac mimeticsSensitized cell
The invention relates to conformationally constrained mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.
Owner:RGT UNIV OF MICHIGAN
Operation mode and apparatus of short distance nitration-anaerobic ammoxidation batched biomembrane denitrogenation
InactiveCN1927739AToxic reductionControl the maximum cumulative concentrationTreatment with aerobic and anaerobic processesSludgeElectron donor
One kind of short range nitrifying-anaerobic aminoxidizing sequencing batch type denitrifying biomembrane mode and plant is disclosed. The limited aerating mode with real-time control of the sewage temperature inside the reactor and high frequency alternation between aeration and anaeration can inhibit the growth of nitrite oxidizing bacteria and denitrifying bacteria so that the aminoxidizing bacteria and the anaerobic aminoxidizing bacteria become the dominant bacteria in the nitrifying and denitrifying stages. In the nitrifying stage, nitrification is stopped in the nitrite step; and in the denitrifying stage, ammonia nitrogen acts as the direct electron donor to reduce nitrite. The plant is provided with fixed spherical composite stuffing with spherical shell of polypropylene and filled inside biological composite material. Sectional discrete water feeding mode is adopted to feed the sewage to be treated in four stages into the reactor.
Owner:HUNAN UNIV
Methods, compositions, and kits for the treatment of medical conditions
The invention features methods, compositions, and kits for treating an immunoinflammatory disorder, an ophthalmic disorder, a musculoskeletal disorder or pain associated therewith, a periodontal disease, or a disease or condition associated with an increased serum CRP level.
Owner:THERAOPTICS
Pharmaceutical compositions and methods to vaccinate against candidiasis
InactiveUS20030124134A1Treat prevent alleviateToxic reductionPeptide/protein ingredientsSnake antigen ingredientsHospitalized patientsVirulent characteristics
A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.
Owner:LOS ANGELES BIOMEDICAL RES INST AT UCLA HARBOR MEDICAL CENT +1
Marine antifouling coating compositions
InactiveUS7335248B2Toxic reductionMinimize bio-foulingBiocideSulfur/selenium/tellurium active ingredientsMarine coatingsOrganism
Owner:NOVUS INTERNATIONAL INC
Therapeutic regimens for administering drug combinations
InactiveUS20050112199A1Good curative effectIncrease the length of timePowder deliveryOrganic active ingredientsDosing regimenRegimen
Owner:COMBINATORX
Post-coupling synthetic approach for polymeric antioxidants
A method of preparing an antioxidant polymer includes forming or obtaining a first polymer having reactive pendant groups, where the first polymer does not include cyclic anhydride repeat units, and derivatizing the first polymer with an antioxidant. Another method of preparing an antioxidant polymer includes forming or obtaining a first polymer having reactive pendant groups and derivatizing the first polymer with an antioxidant, where the antioxidant is attached to the first polymer by an acetal, amide, amine, carbamate, carbonate, ester, ether or thioether linkage or by a carbon-carbon bond. The invention is also directed to polymers that are generally prepared by these methods, compositions that include such polymers and methods of using such polymers.
Owner:UNIVERSITY OF MASSACHUSETTS LOWELL
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com